How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

被引:51
作者
Arnolds, S. [1 ]
Kuglin, B. [1 ]
Kapitza, C. [1 ]
Heise, T. [1 ]
机构
[1] Stoffwechselforsch GmbH, PROFIL Inst, D-41460 Neuss, Germany
关键词
TO-TARGET TRIAL; NEUTRAL PROTAMINE HAGEDORN; WITHIN-SUBJECT VARIABILITY; GLUCOSE-LOWERING DRUGS; FASTING BLOOD-GLUCOSE; HUMAN NPH INSULIN; GLYCEMIC CONTROL; BOLUS REGIMEN; DOUBLE-BLIND; DOSE-RESPONSE;
D O I
10.1111/j.1742-1241.2010.02470.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This pedagogical review illustrates the differences between pharmacokinetic (PK) and pharmacodynamic (PD) measures, using insulin therapy as the primary example. The main conclusion is that PD parameters are of greater clinical significance for insulin therapy than PK parameters. The glucose-clamp technique, the optimal method for determining insulin PD, is explained so that the reader can understand the important studies in the literature. Key glucose-clamp studies that compare two basal insulin analogues - insulin glargine and insulin detemir - to Neutral Protamine Hagedorn insulin and to each other are then presented. The review further explains how PD parameters have been translated into useful clinical concepts and simple titration algorithms for everyday clinical practice. Finally, the necessity of overcoming patient and/or physician barriers to insulin therapy and providing continuing education and training is emphasised.
引用
收藏
页码:1415 / 1424
页数:10
相关论文
共 63 条
[1]   Dosing of insulin glargine in the treatment of type 2 diabetes [J].
Barnett, Anthony .
CLINICAL THERAPEUTICS, 2007, 29 (06) :987-999
[2]   Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial [J].
Bartley, P. C. ;
Bogoev, M. ;
Larsen, J. ;
Philotheou, A. .
DIABETIC MEDICINE, 2008, 25 (04) :442-449
[3]   Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials [J].
Bazzano, L. A. ;
Lee, L. J. ;
Shi, L. ;
Reynolds, K. ;
Jackson, J. A. ;
Fonseca, V. .
DIABETIC MEDICINE, 2008, 25 (08) :924-932
[5]   Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETM study [J].
Blonde, L. ;
Merilainen, M. ;
Karwe, V. ;
Raskin, P. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :623-631
[6]  
Bock G, 2008, DIABETOLOGIA, V51, pS390
[7]   Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes [J].
Bott, S ;
Tusek, C ;
Jacobsen, LV ;
Endahl, L ;
Draeger, E ;
Kapitza, C ;
Heise, T .
DIABETIC MEDICINE, 2006, 23 (05) :522-528
[8]   Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes [J].
Danne, T ;
Lüpke, K ;
Walte, K ;
von Schuetz, W ;
Gall, MA .
DIABETES CARE, 2003, 26 (11) :3087-3092
[9]   Improvement of glycemic control in subjects with poorly controlled type 2 diabetes - Comparison of two treatment algorithms using insulin glargine [J].
Davies, M ;
Storms, F ;
Shutler, S ;
Bianchi-Biscay, M ;
Gomis, R .
DIABETES CARE, 2005, 28 (06) :1282-1288
[10]   IMPROVING INSULIN THERAPY - ACHIEVEMENTS AND CHALLENGES [J].
GALLOWAY, JA ;
CHANCE, RE .
HORMONE AND METABOLIC RESEARCH, 1994, 26 (12) :591-598